BMP-2 vs Palifermin
Head-to-head comparison of BMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BMP-2 | Palifermin |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Bone Morphogenetic Protein-2 | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) |
| Molecular Weight | 26000 Da | 16.3 kDa |
| Half-Life | short, localized exposure | 4–6 hours |
| Amino Acids | 114 | 140 |
| Typical Dose | 1.5 mg/mL local implant | 60 µg/kg/day |
| Route | Local/Implant | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 1500 | 250 |
| Research Status | Clinical | Clinical |
BMP-2 Benefits
- ✓promotes osteogenesis
- ✓supports nonunion healing
- ✓enhances scaffold-based repair
- ✓may improve defect fill
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
BMP-2 Dosing
local implantation on collagen sponge|single intraoperative dose|procedure-specific scaffold delivery
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
BMP-2 Side Effects
- ⚠local inflammation
- ⚠ectopic bone formation
- ⚠edema
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Research Overview
BMP-2
rhBMP-2 has strong clinical and translational literature for bone regeneration, spinal fusion, and defect repair. Its use is primarily local because systemic exposure is not the intended mechanism.
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.